Jarad Martin, Professor of Medicine and Public Health, shared a post by Trans Tasman Radiation Oncology Group (TROG Cancer Research) on LinkedIn, adding:
“I reckon running a clinical trial is like running a marathon.
Meeting accrual is a challenge, but half of the race is yet to be run as we enter the follow up and interpretation phases.
Early safety and MRI planning data at American Society for Radiation Oncology (ASTRO) AM in Boston.
Thanks to colleagues and participants for getting us to this milestone.”
Quoting TROG Cancer Research‘s post:
“We’re thrilled to share that our NINJA prostate cancer trial has now completed recruitment, with 472 men enrolled across Australia and New Zealand.
While traditional radiation treatment for prostate cancer can require up to seven weeks of daily treatments, participants in the NINJA trial are completing one of two shorter schedules of stereotactic body radiotherapy (SBRT), as well as receiving androgen deprivation therapy. The trial could lead to prostate cancer radiation therapy being reduced from between 20 and 40 sessions to between five and 14 sessions.
TROG is running the trial in collaboration with ANZUP Cancer Trials Group Limited.
Congratulations to trial lead investigators Prof Jarad Martin and Dr Mark Sidhom and all the trial sites on reaching this significant milestone.
